title: Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas.
abstract: OBJECTIVE
  Several diagnostic trials have indicated that the combined use of (18)F-fluoroethyl-L: -tyrosine (FET) PET and MRI may be superior to MRI alone in selecting the biopsy site for the diagnosis of gliomas. We estimated the cost-effectiveness of the use of amino acid PET compared to MRI alone from the perspective of the German statutory health insurance.
  
  
  METHODS
  To evaluate the incremental cost-effectiveness of the use of amino acid PET, a decision tree model was built. The effectiveness of FET PET was determined by the probability of a correct diagnosis. Costs were estimated for a baseline scenario and for a more expensive scenario in which disease severity was considered. The robustness of the results was tested using deterministic and probabilistic sensitivity analyses.
  
  
  RESULTS
  The combined use of PET and MRI resulted in an increase of 18.5% in the likelihood of a correct diagnosis. The incremental cost-effectiveness ratio for one additional correct diagnosis using FET PET was €6,405 for the baseline scenario and €9,114 for the scenario based on higher disease severity. The probabilistic sensitivity analysis confirmed the robustness of the results.
  
  
  CONCLUSIONS
  The model indicates that the use of amino acid PET may be cost-effective in patients with glioma. As a result of several limitations in the data used for the model, further studies are needed to confirm the results.
authors.affiliation: Department of Nuclear Medicine of the Heinrich-Heine University of Duesseldorf, Research Centre Juelich, 52426 Juelich, Germany. a.heinzel@fz-juelich.de
authors.forename: Alexander
authors.initials: A
authors.lastname: Heinzel
authors.forename: Stephanie
authors.initials: S
authors.lastname: Stock
authors.forename: Karl-Josef
authors.initials: KJ
authors.lastname: Langen
authors.forename: Dirk
authors.initials: D
authors.lastname: Müller
mesh_terms: D001706:Biopsy; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000191:economics / Q000473:pathology; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D005910:Glioma / Q000000981:diagnostic imaging* / Q000191:economics / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D009010:Monte Carlo Method; D049268:Positron-Emission Tomography / Q000191:economics* / Q000379:methods*; D019275:Radiopharmaceuticals / Q000191:economics; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000191:economics
chemical_list: D019275:Radiopharmaceuticals; C545932:(18F)fluoroethyltyrosine; D014443:Tyrosine